` VCNX (Vaccinex Inc) vs S&P 500 Comparison - Alpha Spread

VCNX
vs
S&P 500

Over the past 12 months, VCNX has underperformed S&P 500, delivering a return of -88% compared to the S&P 500's +13% growth.

Stocks Performance
VCNX vs S&P 500

Loading
VCNX
S&P 500
Add Stock

Performance Gap
VCNX vs S&P 500

Loading
VCNX
S&P 500
Difference
www.alphaspread.com

Performance By Year
VCNX vs S&P 500

Loading
VCNX
S&P 500
Add Stock

Competitors Performance
Vaccinex Inc vs Peers

S&P 500
VCNX
ABBV
AMGN
GILD
VRTX
Add Stock

Vaccinex Inc
Glance View

Market Cap
2.4m USD
Industry
Biotechnology

Vaccinex, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Rochester, New York and currently employs 39 full-time employees. The company went IPO on 2018-08-09. The firm is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate, pepinemab (VX15/2503), is a humanized monoclonal antibody that binds and blocks the signaling activity of semaphorin 4D (SEMA4D). The company is focused on the development of pepinemab for the treatment of certain cancer indications, in particular, head and neck squamous cell carcinoma (HNSCC) as well as neurodegenerative diseases, including Huntington's disease (HD), and Alzheimer's disease, (AD). The firm has discovered VX5 using its ActivMAb antibody discovery platform. VX5 is a human antibody to CXCL13, a molecule that regulates the formation of immune tissues, and is in preclinical development for the treatment of multiple sclerosis (MS) and for other autoimmune disorders.

VCNX Intrinsic Value
3.14 USD
Undervaluation 71%
Intrinsic Value
Price
Back to Top